-
Je něco špatně v tomto záznamu ?
Mitochondrially targeted tamoxifen as anticancer therapy: case series of patients with renal cell carcinoma treated in a phase I/Ib clinical trial
Z. Bielcikova, L. Werner, J. Stursa, V. Cerny, L. Krizova, J. Spacek, S. Hlousek, M. Vocka, O. Bartosova, M. Pesta, K. Kolostova, P. Klezl, V. Bobek, J. Truksa, S. Stemberkova-Hubackova, L. Petruzelka, P. Michalek, J. Neuzil
Status neindexováno Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu kazuistiky
NLK
Directory of Open Access Journals
od 2017
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-07-01
Health & Medicine (ProQuest)
od 2009-07-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
- Publikační typ
- kazuistiky MeSH
Mitochondrially targeted anticancer drugs (mitocans) that disrupt the energy-producing systems of cancer are emerging as new potential therapeutics. Mitochondrially targeted tamoxifen (MitoTam), an inhibitor of mitochondrial respiration respiratory complex I, is a first-in-class mitocan that was tested in the phase I/Ib MitoTam-01 trial of patients with metastatic cancer. MitoTam exhibited a manageable safety profile and efficacy; among 37% (14/38) of responders, the efficacy was greatest in patients with metastatic renal cell carcinoma (RCC) with a clinical benefit rate of 83% (5/6) of patients. This can be explained by the preferential accumulation of MitoTam in the kidney tissue in preclinical studies. Here we report the mechanism of action and safety profile of MitoTam in a case series of RCC patients. All six patients were males with a median age of 69 years, who had previously received at least three lines of palliative systemic therapy and suffered progressive disease before starting MitoTam. We recorded stable disease in four, partial response in one, and progressive disease (PD) in one patient. The histological subtype matched clear cell RCC (ccRCC) in the five responders and claro-cellular carcinoma with sarcomatoid features in the non-responder. The number of circulating tumor cells (CTCs) was evaluated longitudinally to monitor disease dynamics. Beside the decreased number of CTCs after MitoTam administration, we observed a significant decrease of the mitochondrial network mass in enriched CTCs. Two patients had long-term clinical responses to MitoTam, of 50 and 36 weeks. Both patients discontinued treatment due to adverse events, not PD. Two patients who completed the trial in November 2019 and May 2020 are still alive without subsequent anticancer therapy. The toxicity of MitoTam increased with the dosage but was manageable. The efficacy of MitoTam in pretreated ccRCC patients is linked to the novel mechanism of action of this first-in-class mitochondrially targeted drug.
Department of Oncology General Faculty Hospital U Nemocnice 499 2 Prague 2 128 08 Czech Republic
Institute of Biotechnology Czech Academy of Sciences Prague West Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23022803
- 003
- CZ-PrNML
- 005
- 20240116163136.0
- 007
- ta
- 008
- 240105s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1177/17588359231197957 $2 doi
- 035 __
- $a (PubMed)37786538
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Bielcikova, Zuzana $u Department of Oncology, General Faculty Hospital, U Nemocnice 499/2, Prague 2, 128 08, Czech Republic $1 https://orcid.org/0000000184349848 $7 xx0225233
- 245 10
- $a Mitochondrially targeted tamoxifen as anticancer therapy: case series of patients with renal cell carcinoma treated in a phase I/Ib clinical trial / $c Z. Bielcikova, L. Werner, J. Stursa, V. Cerny, L. Krizova, J. Spacek, S. Hlousek, M. Vocka, O. Bartosova, M. Pesta, K. Kolostova, P. Klezl, V. Bobek, J. Truksa, S. Stemberkova-Hubackova, L. Petruzelka, P. Michalek, J. Neuzil
- 520 9_
- $a Mitochondrially targeted anticancer drugs (mitocans) that disrupt the energy-producing systems of cancer are emerging as new potential therapeutics. Mitochondrially targeted tamoxifen (MitoTam), an inhibitor of mitochondrial respiration respiratory complex I, is a first-in-class mitocan that was tested in the phase I/Ib MitoTam-01 trial of patients with metastatic cancer. MitoTam exhibited a manageable safety profile and efficacy; among 37% (14/38) of responders, the efficacy was greatest in patients with metastatic renal cell carcinoma (RCC) with a clinical benefit rate of 83% (5/6) of patients. This can be explained by the preferential accumulation of MitoTam in the kidney tissue in preclinical studies. Here we report the mechanism of action and safety profile of MitoTam in a case series of RCC patients. All six patients were males with a median age of 69 years, who had previously received at least three lines of palliative systemic therapy and suffered progressive disease before starting MitoTam. We recorded stable disease in four, partial response in one, and progressive disease (PD) in one patient. The histological subtype matched clear cell RCC (ccRCC) in the five responders and claro-cellular carcinoma with sarcomatoid features in the non-responder. The number of circulating tumor cells (CTCs) was evaluated longitudinally to monitor disease dynamics. Beside the decreased number of CTCs after MitoTam administration, we observed a significant decrease of the mitochondrial network mass in enriched CTCs. Two patients had long-term clinical responses to MitoTam, of 50 and 36 weeks. Both patients discontinued treatment due to adverse events, not PD. Two patients who completed the trial in November 2019 and May 2020 are still alive without subsequent anticancer therapy. The toxicity of MitoTam increased with the dosage but was manageable. The efficacy of MitoTam in pretreated ccRCC patients is linked to the novel mechanism of action of this first-in-class mitochondrially targeted drug.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a kazuistiky $7 D002363
- 700 1_
- $a Werner, Lukas $u Institute of Biotechnology, Czech Academy of Sciences, Prumyslova 595, Prague-West 252 50, Czech Republic Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague 4, Czech Republic
- 700 1_
- $a Stursa, Jan $u Institute of Biotechnology, Czech Academy of Sciences, Prague-West, Czech RepublicDiabetes Centre, Institute for Clinical and Experimental Medicine, Prague 4, Czech Republic
- 700 1_
- $a Cerny, Vladimir $u Department of Radiodiagnostics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Krizova, Ludmila $u Department of Oncology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Spacek, Jan $u Department of Oncology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Hlousek, Stanislav $u Department of Oncology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Vocka, Michal $u Department of Oncology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Bartosova, Olga $u Institute of Pharmacology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Pesta, Michal $u Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic
- 700 1_
- $a Kolostova, Katarina $u Laboratory of Personalized Medicine, Oncology Clinic, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
- 700 1_
- $a Klezl, Petr $u Laboratory of Personalized Medicine, Oncology Clinic, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic Urology Clinic, Third Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
- 700 1_
- $a Bobek, Vladimir $u Laboratory of Personalized Medicine, Oncology Clinic, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
- 700 1_
- $a Truksa, Jaroslav $u Institute of Biotechnology, Czech Academy of Sciences, Prague-West, Czech Republic
- 700 1_
- $a Stemberkova-Hubackova, Sona $u Institute of Biotechnology, Czech Academy of Sciences, Prague-West, Czech RepublicDiabetes Centre, Institute for Clinical and Experimental Medicine, Prague 4, Czech Republic
- 700 1_
- $a Petruzelka, Lubos $u Department of Oncology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Michalek, Pavel $u Department of Anesthesiology and Intensive Care, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Neuzil, Jiri $u School of Pharmacy and Medical Science, Griffith University, Southport, Qld 4222, Australia Department of Pediatrics and Inherited Metabolic Diseases, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic Department of Physiology, Faculty of Science, Charles University, and General University Hospital, Prague, Czech Republic Institute of Biotechnology, Czech Academy of Sciences, Prumyslova 595, Prague-West 252 50, Czech Republic
- 773 0_
- $w MED00177175 $t Therapeutic advances in medical oncology $x 1758-8340 $g Roč. 15, č. - (2023), s. 17588359231197957
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37786538 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240105 $b ABA008
- 991 __
- $a 20240116163133 $b ABA008
- 999 __
- $a ok $b bmc $g 2036399 $s 1209248
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 15 $c - $d 17588359231197957 $e 20230930 $i 1758-8340 $m Therapeutic advances in medical oncology $n Ther Adv Med Oncol $x MED00177175
- LZP __
- $a Pubmed-20240105
